Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5694
Gene Symbol: PSMB6
PSMB6
0.010 Biomarker phenotype BEFREE The TCR delta gene configuration, which links each phase of the disease, may represent an early pathogenetic event and makes the emergence of a second malignancy unlikely. 8321022 1993
Entrez Id: 11200
Gene Symbol: CHEK2
CHEK2
0.010 GeneticVariation phenotype BEFREE After reviewing the literature about the natural history of the LFS 2, the incidence of second malignancy (SMN) in RMS survivors 3-6 and the management of extremity RMS 7-9, we are concerned that contemporary RMS treatment, combining non-mutilating surgery with chemoradiotherapy, may be associated with an excessive SMN risk in LFS patients with advanced RMS. 16534790 2007
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.010 Biomarker phenotype BEFREE We report a case of a pediatric patient with NBS, who developed t(9;11)/AF9-MLL-positive AML as a second malignancy after successful treatment of T-NHL. 24619942 2014
Entrez Id: 7515
Gene Symbol: XRCC1
XRCC1
0.010 Biomarker phenotype BEFREE No significant association with the development of second neoplasms was observed for the XRCC1 399Gln, XPD 751Gln, or MGMT 84Phe or 143Ile alleles. 16369171 2005
Entrez Id: 7528
Gene Symbol: YY1
YY1
0.010 Biomarker phenotype BEFREE The TCR delta gene configuration, which links each phase of the disease, may represent an early pathogenetic event and makes the emergence of a second malignancy unlikely. 8321022 1993
Entrez Id: 4914
Gene Symbol: NTRK1
NTRK1
0.010 GeneticVariation phenotype BEFREE Familial MTC with <i>RET</i> exon 8 Gly533Cys mutation: origin and prevalence of second malignancy. 28951487 2017
Entrez Id: 9518
Gene Symbol: GDF15
GDF15
0.010 Biomarker phenotype BEFREE GDF-15 concentrations in UM patients with overt clinically detectable metastases were significantly higher than those in UM patients with a second malignancy in remission but without clinically detected UM metastases (ANOVA; p < 0.001). 21881845 2012
Entrez Id: 567
Gene Symbol: B2M
B2M
0.010 GeneticVariation phenotype BEFREE At diagnosis, very young patients had a similar rate of adverse cytogenetics, IGHV mutation and ZAP70 expression and had lower beta-2-microglobulin and a lower incidence of second malignancies. 29316456 2018
Entrez Id: 4683
Gene Symbol: NBN
NBN
0.010 GeneticVariation phenotype BEFREE Our results suggest an important role of NBN 1197A>G and XRCC3-316A>G polymorphisms in the development of second neoplasm in patients treated for childhood ALL. 22752646 2012
Entrez Id: 639
Gene Symbol: PRDM1
PRDM1
0.010 Biomarker phenotype BEFREE Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. 21785431 2011
Entrez Id: 4489
Gene Symbol: MT1A
MT1A
0.010 GeneticVariation phenotype BEFREE Familial MTC with <i>RET</i> exon 8 Gly533Cys mutation: origin and prevalence of second malignancy. 28951487 2017
Entrez Id: 51750
Gene Symbol: RTEL1
RTEL1
0.010 Biomarker phenotype BEFREE We report a case of a pediatric patient with NBS, who developed t(9;11)/AF9-MLL-positive AML as a second malignancy after successful treatment of T-NHL. 24619942 2014
Entrez Id: 1649
Gene Symbol: DDIT3
DDIT3
0.010 Biomarker phenotype BEFREE There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). 29356608 2018
Entrez Id: 100048912
Gene Symbol: CDKN2B-AS1
CDKN2B-AS1
0.010 GeneticVariation phenotype BEFREE By comparison with the other germ line deletions at the CDKN2A, CDKN2B and CDKN2BAS gene cluster reported in melanoma susceptible families, the deletion detected in the two sisters is peculiar for its de novo origin and for its extension, as it represents the largest constitutive deletion at 9p21.3 region identified so far.In addition, the two studied cases add to other evidence indicating association of melanoma with exposure to ionizing radiation and with second neoplasm after childhood cancer. 24884915 2014
Entrez Id: 4524
Gene Symbol: MTHFR
MTHFR
0.010 GeneticVariation phenotype BEFREE MTHFR genotypes were determined in DNA samples isolated from archived bone marrow smears of 15 patients with a second malignancy and a matched control group of 30 patients who did not developed a second malignancy after the treatment for ALL. 16019535 2005
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.010 Biomarker phenotype BEFREE Following the involvement of KRAS mutation in many tumors' pathogenesis, analysis of KRAS was performed in patients with also second neoplasms.Forty-six out of 128 GIST patients (35.9%) had a second neoplasm. 27661019 2016
Entrez Id: 28514
Gene Symbol: DLL1
DLL1
0.010 Biomarker phenotype BEFREE The TCR delta gene configuration, which links each phase of the disease, may represent an early pathogenetic event and makes the emergence of a second malignancy unlikely. 8321022 1993
Entrez Id: 102724971
Gene Symbol: LOC102724971
LOC102724971
0.010 GeneticVariation phenotype BEFREE At diagnosis, very young patients had a similar rate of adverse cytogenetics, IGHV mutation and ZAP70 expression and had lower beta-2-microglobulin and a lower incidence of second malignancies. 29316456 2018
Entrez Id: 8314
Gene Symbol: BAP1
BAP1
0.010 GeneticVariation phenotype BEFREE Analysis of the pooled cohort of germline BAP1 mutation MM showed that patients with peritoneal MM (median survival of 10 years, P = 0.0571), or with a second malignancy in addition to MM (median survival of 10 years, P = 0.0716), survived for a longer time compared with patients who only had pleural MM, or MM patients without a second malignancy, respectively. 25380601 2015
Entrez Id: 5156
Gene Symbol: PDGFRA
PDGFRA
0.010 Biomarker phenotype BEFREE This result provides insight into the possible application of PDGFRA-targeted therapy in these second malignancies. 29644394 2018
Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
0.010 GeneticVariation phenotype BEFREE At diagnosis, very young patients had a similar rate of adverse cytogenetics, IGHV mutation and ZAP70 expression and had lower beta-2-microglobulin and a lower incidence of second malignancies. 29316456 2018
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.010 GeneticVariation phenotype BEFREE By comparison with the other germ line deletions at the CDKN2A, CDKN2B and CDKN2BAS gene cluster reported in melanoma susceptible families, the deletion detected in the two sisters is peculiar for its de novo origin and for its extension, as it represents the largest constitutive deletion at 9p21.3 region identified so far.In addition, the two studied cases add to other evidence indicating association of melanoma with exposure to ionizing radiation and with second neoplasm after childhood cancer. 24884915 2014
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
0.010 AlteredExpression phenotype LHGDN Prognostic significance of cyclooxygenase-2 overexpression in glottic cancer. 18172254 2008
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.010 GeneticVariation phenotype BEFREE The second malignancies in this cohort affected overall survival and suggest the possibility of other germline mutations in addition to BRCA2 in male patients with breast cancer. 28171879 2017
Entrez Id: 2068
Gene Symbol: ERCC2
ERCC2
0.010 GeneticVariation phenotype LHGDN XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer. 15298945 2004